Skip to main content
SpringerLink
Log in

p16 Overexpression: A Potential Early Indicator of Transformation in Ovarian Carcinoma

  • Published:
The Journal of the Society for Gynecologic Investigation: JSGI Aims and scope Submit manuscript

Abstract

Objective

The recently cloned gene p16 (MST1) has been identified as a putative tumor suppressor gene that binds to CDK4 and CDK6 (cyclin-dependent kinases), preventing their interaction with cyclin D1 and thereby preventing cell cycle progression at the G1 stage. In addition, the p16 gene has been shown to have a high frequency of mutation in some tumor cell lines; however, it has also been shown that a much lower frequency of mutation occurs in primary tumors. This study investigated the mRNA expression level and mutation status of the p16 gene in ovarian tumors.

Methods

We performed quantitative polymerase chain reaction and direct cDNA sequencing analysis. To confirm the p16 protein level in ovarian tumors, Western blotting and immunohistochemical staining were performed. Expression levels of mRNA for the p16 gene relative to the β-tubulin gene were examined in 32 ovarian tumors (24 carcinomas, six low malignant potential tumors, and two benign tumors) and six normal ovaries.

Results

The mRNA expression level of p16 was significantly elevated in 28 ovarian tumors (22 carcinomas, five low malignant potential tumors, and one benign tumor) compared with that of normal ovaries. Western blotting analysis and immunohistochemical staining confirmed elevated p16 protein levels in ovarian tumor samples. Among 32 ovarian tumors, cDNA sequencing of the p16 gene showed no p16 mutation resulting in a coding error, although one silent mutation and three polymorphisms were found.

Conclusions

Although p16 is seldom mutated in ovarian tumors, the overexpression of p16 in most ovarian tumor cases indicates a dysfunction in the regulatory complex for G1 arrest. Therefore, overexpression of p16 may be an important early event in the neoplastic transformation of the ovarian epithelium.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Hartwell LH, Kastan MB. Cell cycle control and cancer. Science 1994;266:1821–8.

    Article  CAS  PubMed  Google Scholar 

  2. Hunter T. Braking the cycle. Cell 1993;75:839–41.

    Article  CAS  PubMed  Google Scholar 

  3. Peter M, Herskowitz I. Joining the complex: Cyclin-dependent kinase inhibitory’ proteins and the cell cycle. Cell 1994;79:181–4.

    Article  CAS  PubMed  Google Scholar 

  4. Li Y, Nichols MA, Shay JW, Xiong Y. Transcriptional repression of the D-type cyclin-dependent kinase inhibitor p16 by the retinoblastoma susceptibility gene product pRb. Cancer Res 1994;54:6078–82.

    CAS  PubMed  Google Scholar 

  5. Matsushima H, Ewen ME, Strom DK, et al. Identification and properties of an atypical catalytic subunit (p34psk-33/cdk4) for mammalian D type Gl cyclins. Cell 1992;71:323–34.

    Article  Google Scholar 

  6. Weinberg RA. The retinoblastoma protein and cell cycle control. Cell 1995;81:323–30.

    Article  CAS  PubMed  Google Scholar 

  7. Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 1993;366:704–7.

    Article  CAS  PubMed  Google Scholar 

  8. Kamb A, Grins NA, Weaver-Feldhaus J. et al. A cell cycle regulator potentially involved in genesis of many tumor types. Science 1994;264:436–40.

    Article  CAS  PubMed  Google Scholar 

  9. Nobon T, Miura K, We DJ, Lois A, Takabayashi K, Carson D. Deletion of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 1994;368:753–6.

    Article  Google Scholar 

  10. Cairns P, Mao L, Merlo A, et al. Rates of p16 (MTS1) mutations in primary tumors with 9p loss. Science 1994;265:415–6.

    Article  CAS  PubMed  Google Scholar 

  11. Spruck CH III, Gonzalez-Zulueta M, Shibata A, et al. p16 gene in uncultured tumors. Nature 1994;370:183–4.

    Article  PubMed  Google Scholar 

  12. Okamoto A, Demetrick DJ, Spillare EA, et al. pl6LN,K4 mutations and altered expression in human tumors and cell lines. In: The molecular genetics of cancer. Cold Spring Harbor, New York: Cold Spring Harbor Laboratory Press, 1994:49–57.

    Google Scholar 

  13. Hall JL, Dudley L, Dobner PR, Lewis SA, Cowan NJ. Identification of two human p-tubulin isotypes. Mol Cell Biol 1983;3: 854–62.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Noonan KE, Beck C, Holzmayer TA, et al. Quantitative analysis of MDR1 (multidrug resistance) gene expression in human tumors by polymerase chain reaction. Proc Natl Acad Sci USA 1990;87:7160–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Herman JG, Jen J, Merlo A, Baylin SB. Hypermethylation-associated inactivacion indicates a tumor suppressor role for p15INK4B. Cancer Res 1996;56:722–7.

    CAS  PubMed  Google Scholar 

  16. Herman JG, Merlo A, Mao L, et al. lnactivation of the CDKN2/ p16/MTSl gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res 1995;55:4525–30.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Departments of Obstetrics and Gynecology, Biochemistry and Molecular Biology, and Pathology, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA

    K. Shigemasa MD (Director), C. Hu MD, C. M. West, J. Clarke, G. P. Parham MD, T. H. Parmley MD, S. Korourian PhD, V. V. Baker MD & T. J. O’Brien PhD

  2. Division of Gynecologic Oncology, University of Michigan Medical Center, Ann Arbor, Michigan, USA

    K. Shigemasa MD (Director), C. Hu MD, C. M. West, J. Clarke, G. P. Parham MD, T. H. Parmley MD, S. Korourian PhD, V. V. Baker MD & T. J. O’Brien PhD

Authors
  1. K. Shigemasa MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C. Hu MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. C. M. West
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J. Clarke
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. G. P. Parham MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. T. H. Parmley MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. S. Korourian PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. V. V. Baker MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. T. J. O’Brien PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

The authors acknowledge the participation of the following divisions of the Cooperative Human Tissue Network (CHTN) in providing tumor tissues: Western Division, Case Western Reserve University (Cleveland, OH); Midwestern Division, Ohio State University (Columbus, OH); Eastern Division. NDRI (Philadelphia, PA); Pediatric Division, Children’s Hospital (Columbus, OH); and Southern Division, University of Alabama at Birmingham (Birmingham, AL).

Rights and permissions

Reprints and permissions

About this article

Cite this article

Shigemasa, K., Hu, C., West, C.M. et al. p16 Overexpression: A Potential Early Indicator of Transformation in Ovarian Carcinoma. Reprod. Sci. 4, 95–102 (1997). https://doi.org/10.1016/S1071-5576(97)81110-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1016/S1071-5576(97)81110-0

Key words

Search

Navigation